Abstract
BackgroundSome previous studies explored associations between vascular endothelial growth factor receptor 2 (VEGFR2) polymorphisms and atherosclerotic cardiovascular diseases (ASCVD), with conflicting findings.HypothesisWe thought that VEGFR2 polymorphisms may influence susceptibility to ASCVD. Here, we aimed to better analyze the relationship between VEGFR2 polymorphisms and ASCVD in a larger combined population by performing a meta‐analysis.MethodsWe searched Pubmed, Embase, and Web of Science for related articles. We calculated odds ratio (OR) and 95% confidence interval (CI) to estimate whether there are genetic associations between VEGFR2 polymorphisms and ASCVD. ResultsTen studies were included for this meta‐analysis (5474 cases and 8584 controls). VEGFR2 rs1870377 (dominant comparison: 0.81 (0.73‐0.89), I 2 = 56%; recessive comparison: 1.40 (1.25‐1.57), I 2 = 34%; allele comparison: 0.81 (0.76‐0.87), I 2 = 0%), rs2071559 (dominant comparison: 0.83 (0.76‐0.91), I 2 = 0%; recessive comparison: 1.22 (1.07‐1.38), I 2 = 0%; allele comparison: 0.86 (0.81‐0.92), I 2 = 0%) and rs2305948 (dominant comparison: 0.79 (0.72‐0.87), I 2 = 25%; recessive comparison: 1.44 (1.08‐1.92), I 2 = 60%; allele comparison: 0.79 (0.68‐0.92), I 2 = 73%) polymorphisms were all found to be significantly associated with susceptibility to ASCVD in general population. Subgroup analyses by type of disease revealed similar significant findings for rs1870377, rs2071559, and rs2305948 polymorphisms in coronary artery disease (CAD) subgroup. Besides, positive results were also found for rs1870377 polymorphism in ischemic stroke (IS) subgroup.ConclusionsIn summary, this meta‐analysis proved that these VEGFR2 polymorphisms could be used to identify individual with elevated susceptibility to ASCVD.
Highlights
Atherosclerotic cardiovascular diseases (ASCVD) usually manifest as coronary artery disease (CAD), ischemic stroke (IS) and peripheral arterial disease (PAD).[1]
The precise pathogenesis mechanism of atherosclerotic cardiovascular diseases (ASCVD) is still unrevealed, it was thought that genetic factors may contribute a lot to its development
Using the combination of these susceptible genetic loci to predict the risk of developing ASCVD in general population was demonstrated to be effective and cost-saving.[7]
Summary
Atherosclerotic cardiovascular diseases (ASCVD) usually manifest as coronary artery disease (CAD), ischemic stroke (IS) and peripheral arterial disease (PAD).[1]. Using the combination of these susceptible genetic loci to predict the risk of developing ASCVD in general population was demonstrated to be effective and cost-saving.[7]. Some previous studies explored associations between vascular endothelial growth factor receptor 2 (VEGFR2) polymorphisms and atherosclerotic cardiovascular diseases (ASCVD), with conflicting findings. VEGFR2 rs1870377 (dominant comparison: 0.81 (0.73-0.89), I2 = 56%; recessive comparison: 1.40 (1.25-1.57), I2 = 34%; allele comparison: 0.81 (0.76-0.87), I2 = 0%), rs2071559 (dominant comparison: 0.83 (0.76-0.91), I2 = 0%; recessive comparison: 1.22 (1.07-1.38), I2 = 0%; allele comparison: 0.86 (0.81-0.92), I2 = 0%) and rs2305948 (dominant comparison: 0.79 (0.72-0.87), I2 = 25%; recessive comparison: 1.44 (1.08-1.92), I2 = 60%; allele comparison: 0.79 (0.68-0.92), I2 = 73%) polymorphisms were all found to be significantly associated with susceptibility to ASCVD in general population. Conclusions: In summary, this meta-analysis proved that these VEGFR2 polymorphisms could be used to identify individual with elevated susceptibility to ASCVD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
